Crohn’s Disease (CD)
Log out
to your PfizerFlex
Patient Support Program
for ABRILADA
Crohn’s Disease (CD)
Crohn’s disease (CD) is a chronic condition where part of the lining of the digestive system becomes inflamed, most commonly the last part of the small intestine and the bowel (colon). CD usually starts with repeated bouts of symptoms (called flares) lasting weeks or months, which are followed by periods when the condition improves (called remission). CD is slightly more frequent in women than in men. It can start at any age, but is most likely to develop in people between the ages of 15 and 30.
ABRILADA is used to treat adults with Crohn’s disease (CD) and children 13–17 years, weighing ≥40 kg who have severe CD or CD that has not responded to other usual treatments.
Your immune system works to protect your body from bacteria, viruses, and other foreign agents. In CD, the immune system mistakenly recognizes the body as foreign and attacks healthy body cells.
When you have CD, your immune system overproduces a substance called TNF-alpha (which stands for tumour necrosis factor alpha). The extra TNF-alpha can attack normal healthy body tissues and cause inflammation, especially in the digestive tract.
The way ABRILADA works is by binding to TNF-alpha and decreasing the inflammation process of CD. However, ABRILADA can also lower the body’s ability to fight infections, and taking it can make you or your child more prone to getting infections, or make any infection worse.
ABRILADA is administered by injection under the skin, also called a subcutaneous injection.
ABRILADA ®, Pfizer Inc., owner/ Pfizer Canada ULC, Licensee
PFIZERFLEX TM, Pfizer Inc., owner/ Pfizer Canada ULC, Licensee
© 2024 Pfizer Canada ULC, Kirkland, Quebec H9J 2M5
PP-ABD-CAN-0037-EN
